RT Journal Article SR Electronic T1 GALR1 Methylation in Vaginal Swabs Is Highly Accurate in Identifying Women With Endometrial Cancer JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 1050 OP 1055 DO 10.1097/IGC.0b013e3182959103 VO 23 IS 6 A1 Konstantinos Doufekas A1 Richard Hadwin A1 Raju Kandimalla A1 Allison Jones A1 Tim Mould A1 Susanna Crowe A1 Adeola Olaitan A1 Nicola Macdonald A1 Heidi Fiegl A1 Elisabeth Wik A1 Helga B. Salvesen A1 Martin Widschwendter YR 2013 UL http://ijgc.bmj.com/content/23/6/1050.abstract AB Abstract Endometrial cancer has become the most common gynecological cancer in developed countries. Postmenopausal bleeding is indicative of the disease in only 1 of 10 women with this symptom. A noninvasive tool to identify women with cancer would be highly desirable. We analyzed more than 27,000 CpGs in normal endometrial tissue (n = 23) and endometrial cancers (n = 64) and found that DNA methylation of GALR1 is among the most frequent epigenetic alterations in this cancer. We then developed a real-time polymerase chain reaction–based GALR1 methylation test and applied this test to vaginal swabs from 79 women who presented with postmenopausal bleeding. The receiver operating characteristics area under the curve, describing sensitivity and specificity to correctly identify the 41 women with both premalignant and malignant endometrial changes, was 0.93 (95% confidence interval, 0.87–0.97; P < 0.0001). GALR1 DNA methylation is one of the most common molecular alterations in endometrial cancer, and the presence of GALR1 methylation in vaginal swabs from women with postmenopausal bleeding indicates the presence of endometrial malignancy with a sensitivity of 92.7% and a specificity of 78.9%.